Senti Biosciences Holdings (SNTI) Non-Current Deffered Revenue (2021 - 2022)
Senti Biosciences Holdings (SNTI) posted quarterly Non-Current Deffered Revenue of $7.0 million for Q1 2022, up 3905.68% quarter-over-quarter from $176000.0 in Q4 2021.
Senti Biosciences Holdings (SNTI) Non-Current Deffered Revenue (2021 - 2022) Analysis & Trends
Senti Biosciences Holdings' Non-Current Deffered Revenue history runs 2 years deep, the most recent figure standing at $7.0 million for Q1 2022.
- In Q1 2022, Non-Current Deffered Revenue changed N/A year-over-year to $7.0 million; the TTM figure through Mar 2022 stood at $7.0 million (changed N/A YoY), while the FY2021 annual figure was $176000.0, changed N/A from the prior year.
- Non-Current Deffered Revenue for Q1 2022 stood at $7.0 million, up from $176000.0 in the prior quarter.
- The five-year high for Non-Current Deffered Revenue was $8.0 million in Q2 2021, with the low at $176000.0 in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 147.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Senti Biosciences Holdings | 12.06 Mn | 12.06 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2022 | 7.05 Mn |
| Dec 31, 2021 | 176,000.00 |
| Sep 30, 2021 | 8.05 Mn |
| Jun 30, 2021 | 8.05 Mn |